January Giving Report: New Year, Big Goals
In January 2017, MAPS received over $40,000 in new donations and pledges from 290 supporters. The new year marks our final negotiations with the U.S. Food and Drug Administration (FDA) as we move onto our final Phase 3 trials of MDMA-assisted psychotherapy for PTSD. We are still on track to make MDMA a medicine by 2021, but in the coming years our funding needs will grow substantially. Our Phase 3 studies will cost at least $25 million alone. With $10 million in hand, there’s still a funding gap we need to close.
We extend a special thanks to those who so generously supported MAPS this past month:
General Support
- Anonymous ($10,000)
- Ian Brown ($5,000)
- John Heilemann ($2,500)
- Dal LaMagna ($1,000)
GMP MDMA for MDMA/PTSD Phase 3
- Anonymous ($1,000)
- Anonymous ($1,000)
- Mark Smith ($1,000)
MDMA-Assisted Therapy for Anxiety Associated with Life-Threatening Illness
- John B. Stuppin ($3,000)
MAPS relies on the generosity of individual donors to achieve our mission.Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
Learn how to include MAPS in your will or estate plans.
Learn more about hosting a Global Psychedelic Dinner to fundraise for MAPS.
